{"id":418,"date":"2014-06-04T14:27:44","date_gmt":"2014-06-04T13:27:44","guid":{"rendered":"https:\/\/sclerodermie.ca\/?page_id=418"},"modified":"2024-04-30T16:31:25","modified_gmt":"2024-04-30T20:31:25","slug":"researcher-profiles","status":"publish","type":"page","link":"https:\/\/sclerodermie.ca\/en\/research\/researcher-profiles\/","title":{"rendered":"Researcher Profiles"},"content":{"rendered":"
<\/p>\n

\n\t\t\t\t\t

\n\t\t\t\tScleroderma Research Chair\t\t\t<\/h3>\n\t\t\n\t\t
\n\t\t\t<\/p>\n

Jean-Luc Sen\u00e9cal, M.D.<\/span><\/summary>

<\/p>\n

Jean-Luc Sen\u00e9cal, MD, FRCPC, is a rheumatologist and member of the CHUM\u2019s Rheumatology department. He holds the Scleroderma Research Chair at the University of Montreal.<\/p>\n

Dr. Sen\u00e9cal specializes in the diagnosis and treatment of human systemic autoimmune diseases, such as scleroderma (systemic sclerosis), systemic lupus erythematosus and autoimmune myositis.<\/p>\n

His fundamental research focuses on elucidating the pathophysiological mechanisms underlying these diseases and identifying new treatments.<\/p>\n

Theme:<\/p>\n

Immunopathogenesis and new therapeutic approaches to human systemic autoimmune diseases.<\/p>\n

Research topics:<\/p>\n

Identification, characterization and clinical significance of autoantibodies associated with human systemic autoimmune diseases: scleroderma, systemic lupus erythematosus (SLE) and autoimmune myositis.
\nMolecular mechanisms involved in the immunopathogenesis of these diseases.
\nDevelopment of experimental models of scleroderma.
\nNew therapies for scleroderma.<\/p>\n

 <\/p>\n<\/div><\/details><\/div><\/p>\n

Sabrina Hoa, MD.<\/span><\/summary>

<\/p>\n

Sabrina Hoa, MD MSc FRCPC, is a rheumatologist at the Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), assistant professor in the Department of Medicine at the University of Montreal and clinician-researcher at the CHUM Research Centre.<\/p>\n

Dr. Hoa completed a post-doctoral fellowship in systemic sclerosis and a Masters in Epidemiology at McGill University. The topic of her thesis was on the role of immunosuppressive drugs in the treatment of mild interstitial lung disease associated with systemic sclerosis, as well as on the role of these treatments in the prevention of lung disease. Her training was funded by a Master\u2019s award from the Canadian Institutes for Health Research (CIHR) and by a post-doctoral award from The Arthritis Society. Her research was selected par The Arthritis Society as being part of the Top 10 Research Advances in 2019.<\/p>\n

Research topics:<\/p>\n

Therapeutic approaches and predictors of progression in mild forms of interstitial lung disease associated with systemic sclerosis
\nRole of therapeutics in the prevention of complications associated with systemic sclerosis
\nClinical significance of autoantibodies associated with systemic sclerosis and interstitial lung diseases
\nClassification criteria for scleroderma renal crisis.<\/p>\n

NOTICE TO HEALTHCARE PROFESSIONALS<\/span><\/h2>\n

A clinical trial in scleroderma is currently recruiting at the CHUM. (VITALISScE\u2122 Trial)<\/span><\/p>\n

Please read the details of this clinical trial (VITALISScE\u2122) being conducted in the province of Quebec by Dr Sabrina Hoa\u2019s team at the CHUM. Read more<\/a><\/em><\/p>\n<\/div><\/details><\/div><\/p>\n

\t\t<\/div>\n\n\t\t<\/p>\n

\n\t\t\t\t\t

\n\t\t\t\tImmunoregulation laboratory at CRCHUM\t\t\t<\/h3>\n\t\t\n\t\t
\n\t\t\t<\/p>\n

Marika Sarfati, M.D.<\/span><\/summary>

Dr. Marika Sarfati, MD, PhD, is Director of the Immunoregulation Laboratory at the CHUM Research Centre, and Full Professor, Department of Medicine, University of Montreal.<\/p>\n

 <\/p>\n

Laboratory staff<\/p>\n